TABLE 1.
Characteristica | Total | Result for participants: |
P value | |
---|---|---|---|---|
Never treated with co-trimoxazole | Ever treated with co-trimoxazole | |||
Participants, no. (%) | 13,431 (100) | 8,166 (61) | 5,265 (39) | |
Yr of baseline visit, median (IQR) | 1998 (1993–2005) | 2000 (1995–2006) | 1996 (1992–2001) | <0.001 |
Female, no. (%) | 3,815 (100) | 2,293 (60) | 1,522 (40) | 0.299 |
Age, median yr (IQR) | 35 (30–42) | 34 (29–41) | 35 (30–43) | <0.001 |
Nadir CD4, median cells/μl (IQR) | 273 (129–448) | 355 (228–525) | 150 (61–274) | <0.001 |
Nadir CD4 of <200 cells/μl, no. (%) | 4,602 (100) | 1,510 (33) | 3,092 (67) | <0.001 |
Risk groups and respective % with nadir CD4 of <200/cells μl, no. (%) | ||||
Heterosexuals | 4,521 (100) | 2,292 (60) | 1,829 (40) | <0.001 |
Nadir CD4 of <200 cells/μl | 1,697 (100) | 510 (30) | 1187 (70) | <0.001 |
IDU | 3,108 (100) | 1,591 (51) | 1,517 (49) | |
Nadir CD4 of <200 cells/μl | 1,084 (100) | 349 (32) | 735 (68) | <0.001 |
MSM | 5,271 (100) | 3,583 (68) | 1,688 (32) | |
Nadir CD4 of <200 cells/μl | 1,618 (100) | 597 (37) | 1021 (63) | <0.001 |
Other | 531 (100) | 300 (57) | 231 (44) | |
Nadir CD4 of <200 cells/μl | 203 (100) | 54 (27) | 149 (73) | <0.001 |
Ethnicity, no. (%) | ||||
Caucasianb | 11,074 (100) | 6,679 (60) | 4,395 (40) | 0.012 |
Other | 2,357 (100) | 1,487 (64) | 870 (37) | |
CDC stage, no. (%) | ||||
A | 8,497 (100) | 6,111 (72) | 2,386 (29) | <0.001 |
B | 2,237 (100) | 1,131 (51) | 1,106 (49) | |
C | 2,697 (100) | 924 (34) | 1,773 (66) | |
Nadir CD4, median cells/μl (IQR) | 273 (129–448) | 355 (228–525) | 150 (61–274) | <0.001 |
TST at enrollment, no. (%) | ||||
Test performed | 8,989 (100) | 5,088 (62) | 3901 (74) | <0.001 |
TST positive | 365 (100) | 270 (5) | 95 (2) | <0.001 |
Abbrevations: IDU, intravenous drug use; MSM, men who have sex with men; TST, tuberculin skin test.
SHCS participants from northwestern Europe, North America, and Australia.